Source link : https://www.newshealth.biz/health-news/more-evidence-backs-il-13-blockade-in-atopic-dermatitis/
An investigational anti-interleukin (IL)-13 monoclonal antibody reduced eczema symptoms and was well-tolerated in adults with moderate to severe atopic dermatitis, a randomized phase II study showed. At 16 weeks, a weekly 720-mg dose of cendakimab led to significantly greater improvements in mean Eczema Area and Severity Index (EASI) scores compared with placebo (mean change of […]
Author : News Health
Publish date : 2024-07-17 17:28:09
Copyright for syndicated content belongs to the linked Source.
Categories